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Abstract. – Hepatitis C virus (HCV) infection
is a major health problem worldwide. Chronic
HCV infection may in the long run cause cirrho-
sis, hepatic decompensation and hepatocellular
carcinoma, with an ultimate disease burden of at
least 350,000 deaths per year worldwide. The
new generation of highly effective direct acting
antivirals (DAA) to treat HCV infection brings
major promises to infected patients in terms of
exceedingly high rates of sustained virological
response (SVR) but also of tolerability, allowing
even the sickest patients to be treated. Even in
the face of the excellent safety and efficacy and
wide theoretical applicability of these regimens,
their introduction is currently facing cost and
access issues denying their use to many pa-
tients in need. Health systems in all countries
are facing a huge problem of distributive justice,
since while they should guarantee individual
rights, among which the right to health in its
broader sense, therefore not limited to healing,
but extending to quality of life, they must also
grant equal access to the healthcare resources
and keep the distribution system sustainable. In
the face of a disease with a relatively unpre-
dictable course, where many but not of all
chronically infected will eventually die of liver
disease, selective allocation of this costly re-
source is debatable. In most countries the fa-
vorite solution has been a stratification of pa-
tients for prioritization of treatment, which
means allowing Interferon-free DAA treatment
only in patients with advanced fibrosis or cirrho-
sis, while keeping on hold persons with lesser
stages of liver disease.
In this report, we will perform an ethical as-
sessment addressing the issues linked to ac-
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cess to new therapies, prioritization and eligibili-
ty criteria, analyzing the meaning of the term
“distributive justice” and the different approach-
es that can guide us (individualistic libertarian-
ism, social utilitarianism and egalitarianism) on
this specific matter. Even if over time the price
of new DAA will be reduced through competition
and eventual patent expiration, the phenomenon
of high drug costs will go on in the next decades
and we need adequate tools to face the prob-
lems of distributive justice that come with it.
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Introduction
Hepatitis C virus (HCV) infection is a major
health problem worldwide. HCV infection causes
chronic hepatitis, potentially leading to cirrhosis,
decompensated cirrhosis, and hepatocellular car-
cinoma (HCC), with an ultimate disease burden
of at least 350,000 deaths per year worldwide1.
The onset and accumulation of hepatic fibrosis is
clinically silent in the early stages of disease, and
identification of disease progression is, therefore,
difficult and intrinsically scarcely predictable2.
The yearly incidence of progression of hepatic fi-
brosis from minimal disease to cirrhosis has been
modeled and estimated. The prevalence of biop-
sy-proven cirrhosis after 20 years of infection
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has varied between 7% (in retrospective studies)
and 18% (in clinical referred settings)3. The risk
of cirrhosis is increased in individuals abusing
alcohol, in those who acquire the disease at an
older age, in those with concomitant obesity, in
men, in immunosuppressed HIV-positive pa-
tients, and in those with recurrent HCV after liv-
er transplantation4. Patients with minimal fibrosis
have a low risk of development of complications
of liver disease during the subsequent two
decades; conversely, patients with bridging fibro-
sis or cirrhosis have a higher risk. Serial assess-
ment of fibrosis over time by liver biopsy or non-
invasive imaging techniques such as fibroelas-
tometry or acoustic resonance imaging samples5
might be needed to detect progression and to
identify patients with advanced fibrosis most in
need of immediate treatment. 
The main goal of treatment for chronic HCV
is cure, and thus prevention of disease progres-
sion. Eradication of HCV, defined by a Sustained
Virological Response (SVR), i.e. HCV RNA <
15 IU/mL 12 weeks after completion of antiviral
therapy and thereafter, is associated with reduc-
tion of both all-cause and liver-related mortality
from HCV6,7. Patients with cirrhosis are at more
immediate risk of complications of liver disease. 
The standard of care for chronic hepatitis C
has been up to 2011 pegylated interferon alfa
(IFN) and ribavirin for 24-72 weeks, with a SVR
in 40 to 50% of treated individuals (a minority of
those infected), and clinically significant adverse
events. Between 2011 and 2013, the introduction
of two first generation HCV protease inhibitors,
boceprevir and telaprevir, to be used in combina-
tion with IFN and ribavirin, obtained a relatively
modest increase in SVR (+ 20%) at the expense
of major toxicities. Favorable responses to inter-
feron-based treatments are less common in pa-
tients with cirrhosis compared with those without
cirrhosis8, and are still unsatisfactory when first-
generation protease inhibitors are combined with
interferon and ribavirin, further increasing the
potential risks of adverse events9. As of today,
numerous second-generation direct-acting antivi-
ral agents (DAA) enabling the use of IFN-free,
easily applicable, all-oral regimens have been ap-
proved in US by the Food and Drug Administra-
tion (FDA) and in the EU by the European Medi-
cines Agency (EMA) and have entered clinical
practice worldwide10. Omitting pegylated IFN
and discarding boceprevir and telaprevir due to
their unfavorable adverse events and tolerability
profile has been made possible by an expedited
design and competitive conduct of DAA combi-
nation trials striving for HCV treatments, fos-
tered by FDA’s “breakthrough” registration path-
way11. 
The regimens approved for clinical use in EU
countries by the EMA12 currently encompass:
1. A nucleoside NS5B inhibitor (sofosbuvir),
with ribavirin; 
2. A nucleoside NS5B inhibitor (sofosbuvir) plus
a protease inhibitor (simeprevir) or an NS5A
inhibitor (daclatasvir), with or without rib-
avirin;
2. A fixed-dose combination of sofosbuvir plus
an NS5A inhibitor (ledipasvir);
3. A fixed dose combination of a non-nucleoside
NS5B inhibitor (dasabuvir) plus a protease in-
hibitor (paritaprevir, boosted with ritonavir)
plus an NS5A inhibitor (ombitasvir), with or
without ribavirin. 
Except for a, recommended only for HCV
genotype 2, all others cover all HCV genotypes,
but are less effective against genotype 3. Report-
ed rates of success, in terms of SVR, exceed 90%
in all groups of patients, including those with cir-
rhosis. Other, even more effective DAA combi-
nations are being developed13 for use in the most
difficult to treat and advanced patients, aiming
for 100% of SVR in 100% of patients.
In a setting of restricted access to DAA (relat-
ed to costs, actual availability and the wait for
even better and universally applicable regimens),
the selection of patients for immediate treatment
or deferral entails strict adherence to established,
validated and ethically accountable policies. In
this article we will perform an ethical assessment
addressing the issues linked to access to new
therapies, prioritization and eligibility criteria,
analyzing the meaning of the term distributive
justice and the different approaches that can
guide us regarding the matter.
Even if over time the price of new DAA will
be reduced through competition and eventual
patent expiration, the phenomenon of high drug
costs will go on in the next decades and we need
proper tools to face the problems of distributive
justice that come with it14.
Economical Impact and Access to Care
Enthusiasm for the new regimens has been
dampened by their exceedingly high costs, a ma-
jor obstacle to delivery. The extremely high price
tag of DAA, unbearable for many health care
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introduction is currently facing cost and access
issues denying their use to many patients in
need21, suggesting policies of mixed use of IFN-
containing and IFN-free regimens to reduce
costs, even if the pressure to avoid IFN-contain-
ing regimens has become overwhelming in 2015.
In most countries the (at least early) favorite so-
lution – e.g. in Italy – has been a stratification of
patients for prioritization of treatment, which
means allowing IFN-free DAA treatment only in
patients with advanced fibrosis or cirrhosis, while
keeping on hold persons with lesser stages of liver
disease (so-called ‘informed deferral’ policies)22.
A similar situation arose at the outset of the
HIV/AIDS epidemics, until the availability of
generic compounds removed the price obstacle.
The cost of new DAA treatments seems to be
the most significant barrier to HCV eradication:
surmounting it will require collaboration among
healthcare providers, drug manufacturers, local
and national governments and other stakeholders.
We should, therefore, question about ethically
proper margin profits for drug manufacturers and
ways to limit the high price tags of drugs (patent-
ing, treatment scale up). But most urgently we
have to address the ethical issues linked to access
to new therapies and to eligibility criteria. Even
if over time the price of new DAA will be re-
duced through competition and eventual patent
expiration, the phenomenon of high drug costs
will go on in the next decades and we need prop-
er tools to face the problems of distributive jus-
tice that come with it.
What Does Distributive Justice Mean in
Medicine?
The continuing technical evolution of medi-
cine has brought extraordinary benefits in terms
of health and of Quality of Life (QoL), but has
been accompanied by an exponential growth of
the cost of drugs and medical devices. This en-
tails that as individuals we all have a rightful aim
towards the biggest benefit in terms of health for
ourselves; but as a society, on the other hand, we
need to strike a balance between obtaining the
best possible result for each individual and the
needs of the society as a whole. This means that
the choice that maximizes population’s health or
has the best overall cost/effectiveness is not nec-
essarily the best choice for a specific individual,
and that the best choices may differ for different
individuals19. National States, therefore, are often
facing a huge problem of distributive justice. On
the one hand they need to be able to guarantee
L. Craxì, D. Sacchini, P. Refolo, R. Minacori, V. Daloiso, G. Ricci, et al.
1046
systems, has generated what has been defined as
a “sticker shock” in most countries15. Moreover,
the need for IFN-free combination regimens with
two or more DAA for most of the patients and
longer treatment duration for patients with cir-
rhosis causes a further increase of costs. This is
why it is of uttermost importance to combine
clinical evaluations of “real-life efficacy” of
these regimens with pharmaco-economical
analyses and Health Technology Assessment
(HTA) reports, in order to reach a definite bal-
ance between cost-effectiveness and the actual
margins of negotiation available to provide wide-
spread access to therapy to all in need, avoiding
both economic speculation and medical tourism
to countries that provide these new drugs at low-
er cost. 
However, all-oral HCV drugs on the horizon
are expected to be cost-effective: recent studies
have indicated that for genotype 1, the current
DAA-based regimens are cost-effective16, and re-
cent discounting efforts promise to make them
even more so. 
In addition we must consider that chronic he-
patitis C is a systemic condition and has been
strongly associated with other pathologies such
as diabetes mellitus, cardiovascular disease, psy-
chiatric disorders, renal dysfunction and rheuma-
tologic conditions; if we consider not only liver-
related clinical outcomes, but also extra-hepatic
complications, assessments of cost-effectiveness
of HCV therapy could result even more posi-
tive17. In this sense, pharmaco-economics has
pushed us towards thinking not in mere terms of
price but rather in accounting terms, in order to
evaluate sustainability and current assets together
with the reduction of costs. Cost-effectiveness
and cost are not considered in fact as equivalent:
being cost effective does not guarantee the finan-
cial sustainability in the short term. Hence, since
these treatments should be applied to so many
persons over so brief a period, there would be a
significant budgetary strain.
The current costs of DAA combinations active
against HCV mean that on a global level far less
patients than needed are being treated (only a mi-
nority of the estimated 130-150 million people
infected world-wide are diagnosed and even few-
er are assessed for eligibility and initiated on
treatment) and that no population-wide public
health benefit can be expected for some of the
most heavily affected countries18,19. Even in the
face of the excellent safety and efficacy and wide
theoretical applicability of these regimens20, their
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In this article, we are focusing on micro-al-
locative issues linked to the new treatments for
HCV reminding, however, the great importance
of macro-allocative issues that should therefore
be deeply analyzed.
Individualistic Libertarianism, Social 
Utilitarianism and Egalitarianism 
The ethical assessment of a health care policy
depends on the context and also on the ethical
approach adopted, given that there is not a uni-
versally accepted ethical framework. There are
three fundamental frameworks adopted as refer-
ence within an ethical assessment in this setting:
individualistic libertarianism, social utilitarian-
ism and egalitarianism. Depending on the ethical
model adopted, the meaning of justice in health-
care, and the practical consequences will change.
Individualistic libertarianism privileges indi-
vidual freedom more than social benefit. It aims
to gain the maximum of freedom for each indi-
vidual and conceives justice as the moral oblige
not to damage the others. According to this theo-
ry, the State is compelled not to intervene in
ways that limit individual freedom. When ap-
plied to the distribution of resources in health-
care, justice in liberalistic conception means at a
macro-allocative level deleting every kind of
public healthcare system and giving space to free
marketplace. At a micro-allocative level it means
that the selection of the patient and the prioritiza-
tion for a treatment depends on the capability to
pay and on an individual choice (individual au-
tonomy).
Utilitarianism as a theory of justice is based on
a principle of utility, approving every action that
increases human happiness (by increasing plea-
sure and/or decreasing pain) and disapproving
every action that diminishes it. According to the
utilitarian approach, justice should strive to create
the greatest happiness of the greatest number of
people. A law is just if it consequences in a net
gain in happiness, even at the expense of minori-
ties. Utilitarianism still plays a major part in the
democratic decision-making process; it is a secu-
lar theory requiring no reference to any natural
rights or religious principles defensible by faith.
In macro-allocative justice, utilitarianism priv-
ileges financing those sectors that will increase
social wellness and those areas of healthcare that
will grant return to productivity for the patients.
At a micro-allocative level the sentient patients,
and especially those who are expected to return
to productivity, will be preferred in the selection. 
individual rights, among which the right to health
in its broader sense, extending to compliance and
QoL)23; on the other hand, they need to grant
equal access to the resources and the sustainabili-
ty of the distribution system. It is quite clear that
the ultimate goal for a democratic society would
be obtaining what is best for each individual, but
in doing so it should aim not towards the best
possible cure, but the best cure possible. This ba-
sic assumption is essential, even though it often
leads to a conflict with the desires and aspira-
tions of singles, especially since immediate ac-
cess to information about new and potentially ef-
fective treatments is easily available to anyone.
The prior considerations should make clear why
it is necessary and urgent to perform an ethical
assessment about access and prioritization of
new DAA treatments. 
An ethical assessment about health care policy
means judging it in terms of justice/injustice. The
principle of justice could be described as the
moral obligation to act on the basis of fair adju-
dication between competing claims. As such, it is
linked to fairness, entitlement and equality. Jus-
tice is concerned with the equitable distribution
of benefits and burdens to individuals in social
institutions, and how the rights of various indi-
viduals are realized. In healthcare ethics, justice
can be subdivided into three categories: fair dis-
tribution of scarce resources (distributive jus-
tice), respect for people’s rights (rights based jus-
tice) and respect for morally acceptable laws (le-
gal justice)24.
With regard to distributive justice, which rules
the relationship between the society and its mem-
bers, allocative choices can be made at two levels:
a social level, named “macro-allocative”, and an
individual level, named “micro-allocative”.
Macro-allocative decisions are policy decisions
about which programs and services should be of-
fered in a context of scarcity and how public fund-
ing should be distributed between different levels
of assistance: for example which part of the na-
tional budget must be directed to healthcare, how
to distribute it into different programs, which dis-
eases should come first, and so on. Micro-alloca-
tive decisions, also called patient-selection, are
about selecting the patients who will receive a
treatment, making a prioritization of the patients
or of the treatments, therefore focusing on deci-
sions that concern the single patient. In any case,
while the fate of individual patients is not directly
at issue in macro-allocative decisions, those deci-
sions do affect individual patients indirectly.
1048
Egalitarianism is a theory that privileges so-
cial benefit at the expense of individual free-
dom, requiring the maximum intervention of the
State and reducing free individual choice to the
minimum, favoring equality for all the people.
Egalitarian doctrines maintain that all humans
are equal in fundamental worth or social status,
advocating the removal of economic inequali-
ties among people. The State should, therefore,
intervene to guarantee minimum standards of
care and assistance. At a macro-allocative level
egalitarianism requires the maximum interven-
tion of the State in healthcare policies, with
more attention to the poorer/disadvantaged peo-
ple. At a micro-allocative level it tends to guar-
antee equal access to cure and the same oppor-
tunities for everyone. We should make great
care not to mistake equality, which can be in-
tended as a mere leveling and equalization, with
equity. What should be equal is the final result,
not the mean used or the amount of resources
invested. Gillon24 emphasizes that justice is
more than mere equality and that people can be
treated unjustly even if they are treated equally.
With reference to Aristotle 25,26, he argues that it
is important to treat equals equally and unequals
unequally in proportion to the morally relevant
inequalities (the criterion for which is still being
debated). Situations will always arise where de-
cisions have to be taken and there are limited
resources, different options and/or other con-
flicting moral concerns. Egalitarianism means
therefore in the healthcare systems giving the
same answer to the same individual need for
care, in order to obtain equal results for all. 
Many different countries in the world have
adopted a model of Welfare State, e.g. in UK
and Italy, based on the egalitarian conception of
distributive justice, which envisages a public
healthcare system with equal access to care for
every individual. In order to give the same an-
swer to the same individual health need, the al-
location system is needs-based and it tends to
give priority to the patients with greater need:
this system satisfies the principle of justice
while placing appropriate emphasis on medical
need. According to this option, in these coun-
tries the ultimate goal for society as a whole is
to obtain what is best for each individual, but in
doing so, it aims not towards the best possible
cure, but the best cure possible. This basic as-
sumption is essential, even though it often leads
to a conflict with the desires and preferences of
individuals. 
Scaling Individual’s Health Need
The crucial problem is therefore identifying,
quantifying and scaling the health need of the pa-
tients, according to the progression of the infec-
tion. Can we really be sure about the progression
of HCV infection for each individual? Can we
quantify the risk?
The patient group that benefits the most from
the new DAA therapies is that with clinically ev-
ident cirrhosis, with decompensated cirrhosis and
with other serious comorbidities. The next group
includes asymptomatic patients with advanced fi-
brosis or cirrhosis, to be identified by an assess-
ment of hepatic fibrosis based on non-invasive
diagnostic measures. While advanced fibrosis are
clearly at highest risk for short-term complica-
tions, it is not clear that persons with lesser de-
grees of fibrosis are not at risk17. 
Therefore, we still need data about the risks of
treatment deferral, also considering that we have
evidences that disease progression is not linear in
chronic hepatitis C27: recent analyses have demon-
strated that rates of fibrosis progression may be
more accelerated than previously thought28. A
treatment deferral could thus run the risk to allow
progression to cirrhosis for a subset of patients,
therefore increasing their future risk of hepatic de-
compensation or HCC17. The problem becomes
more evident for patients with minimal or mild fi-
brosis, as the specific risk factors for disease pro-
gression have not been clearly defined yet, not al-
lowing to have certain indications about the pre-
cise benefit and optimal timing of antiviral thera-
py in patients with early-stage disease. Moreover,
in a prognostic setting, predictions are used to plan
therapeutic choices based on the risk of a specific
outcome, and estimates of probabilities are seldom
based on a single predictor. In fact, physicians nat-
urally integrate several patient’s characteristics
and symptoms to make a prediction: prediction is
therefore inherently multivariable29. Although
deterministic and probabilistic analyses try to
take these aspects into consideration, they often
fail to capture the full complexity of the clinical
decision on the individual patient. In this setting,
more detailed treatment comparisons could be
gained by combining the different variables af-
fecting the achievement of SVR, using multivari-
ate risk modeling30. Last but not least, we should
take into account symptoms of HCV, such as
malaise, fatigue and abdominal pain, which – ac-
cording to Pho et al31 – might lower quality of
life throughout the time that a patient is forced to
wait for therapy. 
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According to Aronsohn and Jensen22, an in-
formed deferral is anyhow needed considering
risks related to inaccurate staging of liver disease
with a biopsy (sampling error), inability to predict
progression of fibrosis and comorbidity changes
over time. We also have to be aware that deferral
requires a system of healthcare delivery that allows
tracking and monitoring of patients in whom treat-
ment is deferred, with serial non-invasive fibrosis
measures while preventive care is provided32.
Recent data show that the health benefit of
waiting for IFN-free therapy instead of immedi-
ate IFN-containing regimen is lost when wait
time for the new regimens is greater than 3 years
for cirrhotic patients and 3.2 years for non-cir-
rhotic patients. Therefore, an analysis on how
long it may be possible to defer IFN-free treat-
ments without prejudice for a patient’s health can
be a useful tool, but cannot be used to justify the
status quo and the adoption of a double track for
treatment. In this sense, clinicians’ analysis on
therapeutic options and deferral “pros” and
“cons” are giving us a definite timeline for facing
and solving price issues of new treatments with-
out prejudice for those who at the time being are
not eligible for the new treatment.
Screening
Given the limited ability to risk-stratify early-
stage patients and the possibility of accelerated
disease progression, together with the high effi-
cacy of new DAA, a compelling argument can be
made to offer treatment to everyone, as recom-
mended by the American Association for the
Study of Liver Diseases (AASLD) and the Infec-
tious Diseases Society of America (IDSA) HCV
Guidance33. Although it can take HCV-infected
individuals 20-30 years to develop serious health
consequences, treating them as early as possible
after diagnosis would probably minimize CHC-
related morbidity and mortality34. On the other
hand, overtreatment of potential non-progressors
could raise the bar of costs beyond affordability
for most countries, thus denying societal benefit
(reduction of global disease burden) without in-
dividual benefits. 
In addition, early treatment harnesses preven-
tive potential by removing infected individuals
from the pool of transmitters soon after infection,
increasing the number of possible infections pre-
vented and reducing associated costs. To date it
is estimated that more than 90% of HCV infected
individuals worldwide are unaware of their HCV
positive status, also due to the fact that chronic
hepatitis is asymptomatic until the developments
of late-stage cirrhosis or HCC35. Therefore iden-
tifying and testing at risk populations would rep-
resent a critical step towards control and ulti-
mately eradication of HCV infection, based on
the concept that treating all patients regardless of
fibrosis stage would be in the long-term the best
cost-effective choice.
Several analyses emphasize the cost-effective-
ness of a birth-cohort screening policy; while
other studies portend that treating younger co-
horts of HCV-infected individuals would maxi-
mize medical costs averted and quality-adjusted
life years gained34,36. It has been estimated that in
the USA birth cohort-based screening has the po-
tential to identify up to 75% more HCV infec-
tions in a specific age group (individuals born
between 1945 and 1965) compared to risk-based
screening, depending on the percentage of the
population that is tested34. However, the cost ef-
fectiveness of this screening strategy is especial-
ly sensitive to treatment uptake rates, requiring a
certain threshold rate to generate sufficient cost
savings and life expectancy gains to offset
screening costs34. 
By converse, the current high price tag of new
DAA keeps the financial stakeholders bound to
stratification and prioritization. Moreover, no co-
herent strategies and resources to implement a
population-wide screening and to systematically
care for a large number of newly diagnosed HCV
patients have been validated37. We definitely
need to be aware of the difference between judg-
ing an intervention as cost-effective and having
available the actual resources in the current mo-
ment to support the intervention. Should the
price of DAA go down as predicted, the ultimate
goal would become control of HCV in the gener-
al population, and hence universal screening
would be needed, to allow for early intervention. 
Some ethical issues arise when discussing uni-
versal screening, besides the obvious problems
linked to privacy. False positives tests (i.e. anti-
HCV positive who are HCV RNA negative)
would cause an unnecessary psychological bur-
den, while false negatives (i.e. HCV RNA posi-
tive missed because of a negative anti-HCV test,
such as the saliva test) would reduce effective-
ness of screening and foster a false sense of reas-
surance. Wrong screening results, as few as they
might be, would also potentially jeopardize fami-
ly and emotional relationships, employment, and
insurance status. Most importantly, in the setting
of possible access to cure, all infected persons
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found by screening should be granted the possi-
bility of an effective, tolerable and affordable
treatment, regardless of the stage of their liver
disease. Last but not least, should screening be
made compulsory, individuals who refuse to be
informed about their infection and health status
would be forced to acknowledge the presence of
infection.
Conclusions
As in many fields in medicine, the balance be-
tween individual rights to HCV care and societal
benefit must be reached by taking into account
factors as diverse as the natural history of the
disease, its actual prevalence, our power to pre-
dict the course and the availability of an effective
cure, and most of all the willingness of each per-
son to be screened and eventually cured for the
condition. Financial, organizational, industrial
and political constraints cannot be held as prima-
ry decision factors, but should be held as cofac-
tors regulating in the short term the ease of ac-
cess to care.
Fine-tuning of the decision process to allocate
therapies will in any case need a further evolu-
tion of knowledge on the long term effects of de-
ferring or denying cure on the disease, and ulti-
mately on the infection burden worldwide.
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